The Validity of Objective Response Rate As A Surrogate For Progression-Free And Overall Survival In The Evaluation of First-Line Chemotherapy For Advanced Non-Small Cell Lung Cancer
Oct 1, 2017, 00:00 AM
10.1016/j.jval.2017.08.135
https://www.valueinhealthjournal.com/article/S1098-3015(17)30469-2/fulltext
Section Title :
Disease-Specific Studies
Section Order :
117
First Page :
A421
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)30469-2&doi=10.1016/j.jval.2017.08.135